USP30 and metastatic malignant neoplasm in the lymph nodes: Similarly, a larger percentage of lower USP30-AS1 was also observed in the patients with lymph node metastasis (63.8 vs. 36.2%, Fig. 2B) and advanced TNM stage (65.9 vs.